Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free TECH Stock Alerts

Bio-Techne (TECH) Financials

Bio-Techne logo
$72.43 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern
Compare
Annual Income Statements for Bio-Techne

Annual Income Statements for Bio-Techne

This table shows Bio-Techne's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 104 76 126 96 229 140 272 285 168 73 182
Consolidated Net Income / (Loss)		 104 76 126 96 229 140 263 285 168 73 182
Net Income / (Loss) Continuing Operations		 104 76 126 96 229 140 263 285 168 73 182
Total Pre-Tax Income 		147 112 126 112 276 148 301 339 186 98 241
Total Operating Income		 151 121 136 147 157 237 297 299 207 102 252
Total Gross Profit		 337 375 432 473 483 633 756 770 770 790 799
Total Revenue		 499 563 643 714 739 931 1,106 1,137 1,159 1,220 1,215
Operating Revenue		 499 563 643 714 739 931 1,106 1,137 1,159 1,220 1,215
Total Cost of Revenue		 162 188 211 241 255 298 349 367 389 429 416
Operating Cost of Revenue		 162 188 211 241 255 298 349 367 389 429 416
Total Operating Expenses		 186 254 296 327 326 396 460 471 563 688 547
Selling, General & Admin Expense		 141 200 241 264 261 325 373 378 466 589 452
Research & Development Expense		 45 54 55 62 65 71 87 92 97 99 95
Total Other Income / (Expense), net		 -3.11 -8.62 -10 -35 119 -89 4.80 40 -21 -3.79 -11
Interest Expense		 1.75 7.36 10 22 19 14 11 11 16 8.51 9.63
Interest & Investment Income		 0.25 0.30 0.41 0.57 0.61 0.47 0.79 3.41 3.32 3.89 4.22
Other Income / (Expense), net		 -1.61 -1.57 -0.45 -14 138 -76 15 48 -8.58 0.83 -5.80
Income Tax Expense		 43 36 -0.20 16 47 8.59 38 53 18 25 59
Basic Earnings per Share		 $2.81 $2.04 $3.36 $2.54 $6.00 $0.91 $1.73 $1.81 $1.07 $0.47 $1.17
Weighted Average Basic Shares Outstanding		 37.19M 37.31M 37.48M 37.78M 38.20M 154.99M 156.87M 157.18M 157.71M 157.52M 155.96M
Diluted Earnings per Share		 $2.80 $2.03 $3.31 $2.47 $5.82 $0.87 $1.66 $1.76 $1.05 $0.46 $1.16
Weighted Average Diluted Shares Outstanding		 37.33M 37.50M 38.06M 38.89M 39.40M 161.93M 164.11M 161.86M 160.77M 159.72M 157.01M
Weighted Average Basic & Diluted Shares Outstanding		 37.20M 37.30M 37.50M 37.80M 38.55M 39.08M 39.21M 158.17M 158.60M 155.55M 156.82M

Quarterly Income Statements for Bio-Techne

This table shows Bio-Techne's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 27 49 41 34 35 23 -18 38 38 51 55
Consolidated Net Income / (Loss)		 27 49 41 34 35 23 -18 38 38 51 55
Net Income / (Loss) Continuing Operations		 27 49 41 34 35 23 -18 38 38 51 55
Total Pre-Tax Income 		33 61 42 40 43 38 -23 48 51 71 71
Total Operating Income		 38 67 46 40 47 39 -24 48 54 75 74
Total Gross Profit		 177 205 203 183 194 215 199 188 191 208 211
Total Revenue		 273 303 306 289 297 316 317 287 296 311 321
Operating Revenue		 273 303 306 289 297 316 317 287 296 311 321
Total Cost of Revenue		 96 99 103 106 103 102 118 98 105 103 110
Operating Cost of Revenue		 96 99 103 106 103 102 118 98 105 103 110
Total Operating Expenses		 139 138 158 143 146 176 223 140 137 133 137
Selling, General & Admin Expense		 116 112 134 119 121 151 197 116 114 109 113
Research & Development Expense		 23 26 24 24 25 25 26 24 23 23 24
Total Other Income / (Expense), net		 -4.62 -5.91 -4.16 0.18 -4.54 -0.43 1.00 0.33 -3.68 -4.27 -3.60
Income Tax Expense		 5.92 12 1.07 6.57 7.99 16 -5.18 9.81 13 20 16
Basic Earnings per Share		 $0.17 $0.31 $0.26 $0.21 $0.22 $0.14 ($0.10) $0.25 $0.24 $0.33 $0.35
Weighted Average Basic Shares Outstanding		 157.53M 157.31M 157.71M 158.53M 158.43M 157.37M 157.52M 155.46M 155.84M 156.33M 155.96M
Diluted Earnings per Share		 $0.17 $0.31 $0.26 $0.21 $0.22 $0.14 ($0.11) $0.24 $0.24 $0.32 $0.36
Weighted Average Diluted Shares Outstanding		 160.06M 160.50M 160.77M 161.12M 160.63M 158.94M 159.72M 156.36M 157.00M 157.40M 157.01M
Weighted Average Basic & Diluted Shares Outstanding		 157.19M 157.58M 158.60M 158.89M 158.09M 156.77M 155.55M 155.81M 156.45M 156.57M 156.82M

Annual Cash Flow Statements for Bio-Techne

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 9.71 27 32 -21 46 52 -27 8.00 -29 10 103
Net Cash From Operating Activities		 144 144 170 182 205 352 325 254 299 288 292
Net Cash From Continuing Operating Activities		 144 144 170 182 205 352 325 254 299 288 292
Net Income / (Loss) Continuing Operations		 104 76 126 96 229 140 263 285 168 73 182
Consolidated Net Income / (Loss)		 104 76 126 96 229 140 263 285 168 73 182
Depreciation Expense		 43 60 64 78 83 88 101 107 112 110 97
Non-Cash Adjustments To Reconcile Net Income		 15 36 50 46 -113 124 26 -18 68 142 40
Changes in Operating Assets and Liabilities, net		 -18 -28 -71 -39 6.19 1.03 -65 -120 -49 -38 -28
Net Cash From Investing Activities		 -108 -306 -39 -337 27 -244 -97 -266 -203 -35 -18
Net Cash From Continuing Investing Activities		 -108 -306 -39 -337 27 -244 -97 -266 -203 -35 -18
Purchase of Property, Plant & Equipment		 -17 -15 -21 -25 -52 -44 -45 -38 -63 -31 -29
Acquisitions		 -91 -254 -68 -289 0.00 -225 0.00 -101 -170 0.00 0.00
Purchase of Investments		 0.00 -43 -8.57 -43 -68 -40 -78 -21 -5.53 0.00 0.00
Sale of Property, Plant & Equipment		 - - - - - - - 0.00 0.00 2.45 4.62
Sale and/or Maturity of Investments		 0.78 6.08 58 22 147 66 26 108 35 8.38 6.04
Other Investing Activities, net		 -0.03 0.00 0.68 0.00 - - 0.00 -232 0.00 -15 0.00
Net Cash From Financing Activities		 -23 189 -99 134 -184 -63 -243 23 -122 -254 -169
Net Cash From Continuing Financing Activities		 -23 189 -99 134 -184 -63 -243 23 -122 -254 -169
Repayment of Debt		 -59 -118 -63 -420 -189 -272 -175 -528 -256 -77 -146
Repurchase of Common Equity		 - 0.00 0.00 -15 -50 -43 -161 -20 -80 -276 -42
Payment of Dividends		 -48 -47 -48 -48 -49 -50 -50 -50 -50 -50 -50
Issuance of Debt		 77 369 55 580 40 256 90 620 225 104 0.00
Other Financing Activities, net		 6.02 -15 -43 38 64 46 53 0.92 39 45 68
Effect of Exchange Rate Changes		 -3.51 0.50 - -0.31 - 6.37 -12 -3.36 -2.33 12 -2.24

Quarterly Cash Flow Statements for Bio-Techne

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -19 9.78 12 36 -9.99 -37 22 -17 28 37 55
Net Cash From Operating Activities		 83 81 75 64 84 41 98 28 82 87 95
Net Cash From Continuing Operating Activities		 83 81 75 64 84 41 98 28 82 87 95
Net Income / (Loss) Continuing Operations		 27 49 41 34 35 23 -18 38 38 51 55
Consolidated Net Income / (Loss)		 27 49 41 34 35 23 -18 38 38 51 55
Depreciation Expense		 28 27 28 28 27 28 27 24 25 24 24
Non-Cash Adjustments To Reconcile Net Income		 20 11 26 16 18 8.64 99 1.63 18 13 7.83
Changes in Operating Assets and Liabilities, net		 8.13 -6.09 -20 -14 3.68 -18 -11 -37 1.44 -1.32 8.82
Net Cash From Investing Activities		 -24 -16 -8.81 -22 -5.03 -8.87 0.41 0.61 -5.92 -5.82 -7.06
Net Cash From Continuing Investing Activities		 -24 -16 -8.81 -22 -5.03 -8.87 0.41 0.61 -5.92 -5.82 -7.06
Purchase of Property, Plant & Equipment		 -15 -16 -18 -9.17 -6.82 -10 -4.89 -5.36 -5.92 -9.09 -8.48
Sale and/or Maturity of Investments		 - - 2.18 2.49 - 1.25 -2.65 1.35 - 3.27 1.42
Net Cash From Financing Activities		 -81 -52 -60 -12 -84 -68 -90 -44 -49 -43 -33
Net Cash From Continuing Financing Activities		 -81 -52 -60 -12 -84 -68 -90 -44 -49 -43 -33
Repurchase of Common Equity		 - - - 0.00 - -100 -100 -0.02 - - -42
Payment of Dividends		 -13 -13 -13 -13 -13 -13 -12 -12 -12 -13 -12
Other Financing Activities, net		 4.20 18 23 20 4.53 15 5.99 14 3.48 30 21
Effect of Exchange Rate Changes		 3.42 -2.35 5.28 5.12 -5.47 -1.08 13 -1.21 0.41 -1.19 -0.26

Annual Balance Sheets for Bio-Techne

This table presents Bio-Techne's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 1,130 1,558 1,593 1,884 2,028 2,263 2,295 2,639 2,704 2,558 2,587
Total Current Assets		 254 348 398 413 521 511 606 621 617 608 744
Cash & Equivalents		 64 92 122 101 147 199 173 181 152 162 265
Accounts Receivable		 93 117 120 137 123 145 195 218 241 207 217
Inventories, net		 57 60 86 91 103 117 141 172 180 189 196
Other Current Assets		 7.56 13 11 18 24 17 23 27 34 37 67
Other Current Nonoperating Assets		 - - - - - - - 0.00 9.77 12 0.00
Plant, Property, & Equipment, net		 132 135 145 154 177 208 223 226 251 246 232
Total Noncurrent Assets		 743 1,075 1,049 1,318 1,330 1,544 1,466 1,791 1,835 1,704 1,610
Goodwill		 431 579 598 733 728 843 822 873 973 981 975
Intangible Assets		 311 452 446 579 517 616 532 535 507 366 303
Other Noncurrent Operating Assets		 1.92 44 5.27 5.67 85 85 112 384 356 357 332
Total Liabilities & Shareholders' Equity		 1,130 1,558 1,593 1,884 2,028 2,263 2,295 2,639 2,704 2,558 2,587
Total Liabilities		 250 609 514 719 646 692 589 672 635 639 479
Total Current Liabilities		 54 136 80 102 107 152 176 129 159 176 164
Accounts Payable		 21 17 18 16 23 29 34 26 38 25 27
Accrued Expenses		 8.37 19 20 26 9.09 15 18 15 25 26 20
Current Deferred Revenue		 4.72 5.97 - 9.08 - - 23 23 28 33 36
Current Deferred & Payable Income Tax Liabilities		 1.78 2.48 8.88 5.76 2.38 5.34 13 12 3.71 11 3.59
Current Employee Benefit Liabilities		 15 27 24 29 31 51 62 37 50 66 58
Other Current Liabilities		 - - 8.11 0.00 23 34 13 13 15 16 19
Total Noncurrent Liabilities		 196 473 435 617 540 539 413 544 476 463 315
Long-Term Debt		 92 344 339 493 344 329 243 350 319 346 200
Noncurrent Deferred & Payable Income Tax Liabilities		 63 121 86 90 101 93 99 89 56 6.17 19
Other Noncurrent Operating Liabilities		 42 8.70 9.34 34 94 117 70 105 101 111 95
Total Equity & Noncontrolling Interests		 879 950 1,079 1,166 1,381 1,571 1,701 1,967 2,069 1,919 2,108
Total Preferred & Common Equity		 879 950 1,079 1,166 1,381 1,563 1,702 1,967 2,069 1,919 2,108
Total Common Equity		 879 950 1,079 1,166 1,381 1,563 1,702 1,967 2,069 1,919 2,108
Common Stock		 179 200 247 317 421 535 654 723 822 913 1,035
Retained Earnings		 771 799 877 932 1,057 1,085 1,123 1,309 1,325 1,066 1,144
Accumulated Other Comprehensive Income / (Loss)		 -70 -49 -45 -84 -97 -57 -75 -66 -78 -60 -71

Quarterly Balance Sheets for Bio-Techne

This table presents Bio-Techne's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 2,639 2,755 2,731 2,721 2,704 2,736 2,670 2,644 2,526 2,523 2,551
Total Current Assets		 621 591 591 611 617 649 635 627 610 637 688
Cash & Equivalents		 181 149 130 140 152 188 178 141 145 173 210
Accounts Receivable		 218 205 207 228 241 224 218 237 184 185 215
Inventories, net		 172 186 181 179 180 185 188 191 203 205 201
Other Current Assets		 27 52 40 31 34 43 50 54 77 74 62
Other Current Nonoperating Assets		 0.00 - 27 27 9.77 9.46 1.05 4.70 0.00 0.00 0.00
Plant, Property, & Equipment, net		 226 232 234 244 251 254 250 252 240 234 233
Total Noncurrent Assets		 1,791 1,932 1,906 1,867 1,835 1,834 1,786 1,765 1,676 1,651 1,630
Goodwill		 873 969 980 971 973 983 965 969 979 981 978
Intangible Assets		 535 579 551 526 507 486 461 444 350 335 319
Other Noncurrent Operating Assets		 384 384 375 369 356 365 360 353 347 335 333
Total Liabilities & Shareholders' Equity		 2,639 2,755 2,731 2,721 2,704 2,736 2,670 2,644 2,526 2,523 2,551
Total Liabilities		 672 758 767 707 635 597 592 626 560 512 465
Total Current Liabilities		 129 128 135 150 159 142 161 169 145 140 153
Accounts Payable		 26 28 32 29 38 32 33 32 30 26 23
Accrued Expenses		 15 16 17 18 25 21 28 24 19 20 18
Current Deferred Revenue		 23 25 28 30 28 27 28 32 30 31 38
Current Deferred & Payable Income Tax Liabilities		 12 5.94 6.65 12 3.71 3.14 3.14 3.63 2.85 2.48 2.97
Current Employee Benefit Liabilities		 37 35 33 44 50 42 54 62 44 45 54
Other Current Liabilities		 13 17 17 16 15 18 16 16 18 15 16
Total Noncurrent Liabilities		 544 630 632 557 476 455 431 457 416 371 312
Long-Term Debt		 350 440 447 389 319 300 300 330 300 260 200
Noncurrent Deferred & Payable Income Tax Liabilities		 89 83 72 64 56 50 38 32 11 11 14
Other Noncurrent Operating Liabilities		 105 107 113 104 101 105 93 95 105 100 98
Total Equity & Noncontrolling Interests		 1,967 1,998 1,964 2,014 2,069 2,139 2,078 2,018 1,966 2,011 2,085
Total Preferred & Common Equity		 1,967 1,998 1,964 2,014 2,069 2,139 2,078 2,018 1,966 2,011 2,085
Total Common Equity		 1,967 1,998 1,964 2,014 2,069 2,139 2,078 2,018 1,966 2,011 2,085
Common Stock		 723 748 766 792 822 858 877 904 948 967 1,007
Retained Earnings		 1,309 1,328 1,261 1,298 1,325 1,341 1,287 1,196 1,083 1,107 1,145
Accumulated Other Comprehensive Income / (Loss)		 -66 -78 -64 -75 -78 -60 -86 -82 -64 -62 -67

Annual Metrics And Ratios for Bio-Techne

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - - 156,568,751.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 156,568,751.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 10.34% 12.82% 14.21% 11.04% 3.46% 26.04% 18.75% 2.81% 1.97% 5.23% -0.38%
EBITDA Growth		 -0.29% -6.62% 11.81% 5.56% 78.78% -33.99% 65.58% 9.86% -31.71% -31.25% 61.25%
EBIT Growth		 -3.93% -20.11% 14.04% -1.90% 121.60% -45.21% 92.94% 11.08% -42.82% -47.96% 138.72%
NOPAT Growth		 3.83% -23.19% 66.44% -7.74% 3.75% 71.22% 15.82% -2.68% -25.74% -59.26% 149.69%
Net Income Growth		 -3.03% -27.17% 65.80% -23.84% 138.67% -39.12% 88.49% 8.49% -41.11% -56.34% 147.77%
EPS Growth		 -3.11% -27.50% 63.05% -25.38% 135.63% -39.12% 88.49% 6.02% -40.34% -56.19% 152.17%
Operating Cash Flow Growth		 3.44% -0.30% 18.54% 6.60% 12.99% 71.61% -7.64% -21.79% 17.53% -3.82% 1.57%
Free Cash Flow Firm Growth		 114.68% -685.47% 142.01% -244.71% 213.51% -93.05% 1,889.38% -164.99% 152.14% 172.08% 12.30%
Invested Capital Growth		 8.08% 36.65% 2.96% 21.99% -2.33% 14.39% 1.77% 23.37% 5.18% -6.06% -2.24%
Revenue Q/Q Growth		 3.55% 4.03% 3.82% 1.62% -2.10% 9.81% 2.71% 1.17% 0.41% 0.90% 0.35%
EBITDA Q/Q Growth		 0.67% 5.74% 13.33% -8.39% 10.94% -14.61% 7.41% 15.99% -15.34% -24.68% 35.17%
EBIT Q/Q Growth		 0.08% 4.97% 18.46% -14.25% 13.98% -22.29% 9.59% 21.57% -22.43% -40.04% 60.05%
NOPAT Q/Q Growth		 1.14% 2.63% -1.82% 3.11% 2.90% 18.45% -3.28% 7.12% -16.14% -45.12% 66.25%
Net Income Q/Q Growth		 -0.67% 2.67% 12.58% -20.81% 22.68% -24.05% 21.90% 4.99% -17.19% -44.25% 65.99%
EPS Q/Q Growth		 -0.71% 2.53% 11.45% -21.09% 19.26% -24.05% 21.90% 2.33% -18.60% -45.24% 68.12%
Operating Cash Flow Q/Q Growth		 -0.34% 10.96% 8.95% -4.67% -5.16% 28.09% -5.60% -7.06% -2.57% 8.57% -0.94%
Free Cash Flow Firm Q/Q Growth		 -95.14% 77.41% 24.74% -56.55% 1.13% -92.46% 1,122.05% -13.32% -21.44% 25.44% -1.88%
Invested Capital Q/Q Growth		 1,040.74% -1.56% -3.25% 1.00% 1.15% 12.92% -1.51% 0.38% -0.31% -5.10% -1.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 67.46% 66.53% 67.21% 66.31% 65.41% 67.97% 68.42% 67.72% 66.41% 64.80% 65.77%
EBITDA Margin		 38.42% 31.80% 31.13% 29.60% 51.15% 26.79% 37.35% 39.91% 26.73% 17.46% 28.27%
Operating Margin		 30.18% 21.42% 21.18% 20.55% 21.31% 25.49% 26.83% 26.30% 17.83% 8.38% 20.73%
EBIT Margin		 29.85% 21.14% 21.11% 18.65% 39.94% 17.36% 28.21% 30.48% 17.09% 8.45% 20.25%
Profit (Net Income) Margin		 20.94% 13.51% 19.62% 13.46% 31.04% 14.99% 23.80% 25.11% 14.50% 6.02% 14.97%
Tax Burden Percent		 70.84% 67.96% 100.16% 85.77% 82.93% 94.20% 87.30% 84.29% 90.53% 74.55% 75.56%
Interest Burden Percent		 98.99% 94.07% 92.80% 84.13% 93.70% 91.66% 96.63% 97.75% 93.73% 95.52% 97.80%
Effective Tax Rate		 29.16% 32.04% -0.16% 14.23% 17.07% 5.80% 12.70% 15.71% 9.47% 25.45% 24.44%
Return on Invested Capital (ROIC)		 12.61% 7.88% 11.19% 9.17% 8.76% 14.16% 15.23% 13.16% 8.62% 3.53% 9.21%
ROIC Less NNEP Spread (ROIC-NNEP)		 25.40% 3.20% 6.18% -2.74% 54.23% -67.53% 21.79% 54.21% -3.82% 1.81% -6.66%
Return on Net Nonoperating Assets (RNNOA)		 -0.51% 0.44% 1.24% -0.61% 9.25% -4.70% 0.85% 2.41% -0.29% 0.15% -0.18%
Return on Equity (ROE)		 12.10% 8.32% 12.44% 8.56% 18.01% 9.46% 16.08% 15.57% 8.33% 3.68% 9.03%
Cash Return on Invested Capital (CROIC)		 4.85% -23.10% 8.28% -10.64% 11.12% 0.73% 13.47% -7.77% 3.58% 9.79% 11.47%
Operating Return on Assets (OROA)		 13.59% 8.86% 8.61% 7.66% 15.09% 7.54% 13.69% 14.05% 7.42% 3.92% 9.57%
Return on Assets (ROA)		 9.53% 5.66% 8.01% 5.53% 11.72% 6.51% 11.55% 11.57% 6.29% 2.79% 7.07%
Return on Common Equity (ROCE)		 12.10% 8.32% 12.44% 8.56% 18.01% 9.43% 16.04% 15.57% 8.33% 3.68% 9.03%
Return on Equity Simple (ROE_SIMPLE)		 11.88% 8.01% 11.69% 8.24% 16.60% 8.93% 15.46% 14.52% 8.13% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 107 82 136 126 131 224 259 252 187 76 190
NOPAT Margin		 21.38% 14.56% 21.21% 17.62% 17.67% 24.01% 23.42% 22.17% 16.14% 6.25% 15.66%
Net Nonoperating Expense Percent (NNEP)		 -12.79% 4.68% 5.02% 11.91% -45.47% 81.68% -6.56% -41.05% 12.44% 1.72% 15.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 3.37% 8.25%
Cost of Revenue to Revenue		 32.54% 33.47% 32.79% 33.69% 34.59% 32.03% 31.58% 32.28% 33.59% 35.20% 34.24%
SG&A Expenses to Revenue		 28.23% 35.60% 37.42% 37.02% 35.28% 34.90% 33.72% 33.29% 40.24% 48.25% 37.23%
R&D to Revenue		 9.06% 9.51% 8.60% 8.74% 8.83% 7.58% 7.88% 8.14% 8.34% 8.16% 7.80%
Operating Expenses to Revenue		 37.29% 45.11% 46.03% 45.77% 44.10% 42.49% 41.60% 41.42% 48.58% 56.41% 45.03%
Earnings before Interest and Taxes (EBIT)		 149 119 136 133 295 162 312 346 198 103 246
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 192 179 200 211 378 249 413 454 310 213 343
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.53 4.44 5.00 6.60 7.18 11.05 7.91 6.50 5.45 4.20 5.24
Price to Tangible Book Value (P/TBV)		 28.89 0.00 154.81 0.00 72.76 166.23 38.66 22.86 19.15 14.07 13.32
Price to Revenue (P/Rev)		 7.98 7.49 8.39 10.77 13.43 18.56 12.17 11.24 9.73 6.60 9.09
Price to Earnings (P/E)		 38.13 55.40 42.76 80.06 43.26 123.05 49.47 44.80 67.09 109.72 60.76
Dividend Yield		 1.20% 1.13% 0.89% 0.63% 0.49% 0.29% 0.37% 0.49% 0.45% 0.62% 0.45%
Earnings Yield		 2.62% 1.81% 2.34% 1.25% 2.31% 0.81% 2.02% 2.23% 1.49% 0.91% 1.65%
Enterprise Value to Invested Capital (EV/IC)		 4.53 3.72 4.49 5.33 6.80 10.33 7.85 6.11 5.14 3.94 5.38
Enterprise Value to Revenue (EV/Rev)		 7.98 7.93 8.63 11.25 13.55 18.69 12.18 11.37 9.87 6.75 9.04
Enterprise Value to EBITDA (EV/EBITDA)		 20.77 24.94 27.73 38.02 26.50 69.76 32.61 28.50 36.94 38.68 31.98
Enterprise Value to EBIT (EV/EBIT)		 26.74 37.53 40.90 60.34 33.93 107.63 43.18 37.32 57.77 79.91 44.64
Enterprise Value to NOPAT (EV/NOPAT)		 37.34 54.50 40.70 63.85 76.68 77.84 52.01 51.31 61.17 108.07 57.71
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.63 31.08 32.58 44.24 48.79 49.41 41.40 50.82 38.28 28.65 37.61
Enterprise Value to Free Cash Flow (EV/FCFF)		 97.11 0.00 55.03 0.00 60.42 1,511.35 58.80 0.00 147.48 39.01 46.33
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.11 0.43 0.31 0.44 0.26 0.22 0.15 0.18 0.15 0.18 0.09
Long-Term Debt to Equity		 0.10 0.36 0.31 0.42 0.25 0.21 0.14 0.18 0.15 0.18 0.09
Financial Leverage		 -0.02 0.14 0.20 0.22 0.17 0.07 0.04 0.04 0.08 0.08 0.03
Leverage Ratio		 1.27 1.47 1.55 1.55 1.54 1.45 1.39 1.35 1.32 1.32 1.28
Compound Leverage Factor		 1.26 1.38 1.44 1.30 1.44 1.33 1.35 1.31 1.24 1.26 1.25
Debt to Total Capital		 9.77% 30.10% 23.91% 30.38% 20.80% 18.02% 13.08% 15.24% 13.36% 15.28% 8.66%
Short-Term Debt to Total Capital		 0.39% 4.79% 0.00% 0.95% 1.06% 0.86% 0.64% 0.15% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.39% 25.31% 23.91% 29.43% 19.74% 17.16% 12.44% 15.09% 13.36% 15.28% 8.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.43% -0.04% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 90.23% 69.90% 76.09% 69.62% 79.20% 81.55% 86.96% 84.76% 86.64% 84.72% 91.34%
Debt to EBITDA		 0.50 2.28 1.69 2.41 0.96 1.38 0.62 0.78 1.03 1.62 0.58
Net Debt to EBITDA		 0.00 1.40 0.79 1.62 0.24 0.46 0.02 0.33 0.54 0.86 -0.19
Long-Term Debt to EBITDA		 0.48 1.92 1.69 2.33 0.91 1.32 0.59 0.77 1.03 1.62 0.58
Debt to NOPAT		 0.89 4.99 2.49 4.04 2.78 1.54 0.99 1.40 1.70 4.54 1.05
Net Debt to NOPAT		 -0.01 3.06 1.15 2.72 0.70 0.51 0.03 0.59 0.89 2.41 -0.34
Long-Term Debt to NOPAT		 0.86 4.20 2.49 3.92 2.64 1.47 0.94 1.39 1.70 4.54 1.05
Altman Z-Score		 11.59 5.65 7.99 7.92 11.03 16.50 15.55 13.19 12.22 8.96 15.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.28% 0.23% -0.02% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.69 2.57 5.01 4.05 4.88 3.35 3.44 4.84 3.87 3.46 4.55
Quick Ratio		 3.49 2.03 3.80 2.98 3.69 2.48 2.51 3.29 2.47 2.10 2.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 41 -240 101 -146 166 12 229 -149 78 211 237
Operating Cash Flow to CapEx		 853.10% 946.84% 813.83% 714.73% 396.60% 794.93% 724.31% 665.18% 475.50% 1,006.88% 1,205.27%
Free Cash Flow to Firm to Interest Expense		 23.46 -32.62 9.90 -6.73 8.63 0.83 20.25 -13.27 4.93 24.82 24.62
Operating Cash Flow to Interest Expense		 82.47 19.52 16.72 8.37 10.69 25.24 28.76 22.68 19.00 33.79 30.33
Operating Cash Flow Less CapEx to Interest Expense		 72.80 17.46 14.67 7.20 7.99 22.07 24.79 19.27 15.00 30.44 27.81
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.46 0.42 0.41 0.41 0.38 0.43 0.49 0.46 0.43 0.46 0.47
Accounts Receivable Turnover		 6.11 5.36 5.42 5.54 5.68 6.95 6.50 5.50 5.04 5.44 5.74
Inventory Turnover		 3.04 3.21 2.89 2.72 2.63 2.71 2.71 2.35 2.22 2.33 2.16
Fixed Asset Turnover		 3.81 4.21 4.59 4.77 4.47 4.84 5.13 5.06 4.86 4.91 5.09
Accounts Payable Turnover		 9.52 10.05 11.94 13.88 13.00 11.36 11.04 12.32 12.23 13.57 16.00
Days Sales Outstanding (DSO)		 59.77 68.14 67.30 65.88 64.24 52.52 56.11 66.31 72.41 67.08 63.60
Days Inventory Outstanding (DIO)		 119.91 113.54 126.20 134.08 138.72 134.59 134.81 155.58 164.70 156.92 169.00
Days Payable Outstanding (DPO)		 38.32 36.32 30.56 26.30 28.07 32.12 33.06 29.62 29.83 26.90 22.82
Cash Conversion Cycle (CCC)		 141.35 145.37 162.94 173.66 174.88 154.99 157.85 192.27 207.28 197.10 209.78
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 879 1,201 1,236 1,508 1,473 1,685 1,715 2,116 2,225 2,090 2,044
Invested Capital Turnover		 0.59 0.54 0.53 0.52 0.50 0.59 0.65 0.59 0.53 0.57 0.59
Increase / (Decrease) in Invested Capital		 66 322 36 272 -35 212 30 401 110 -135 -47
Enterprise Value (EV)		 3,983 4,466 5,551 8,034 10,012 17,399 13,467 12,929 11,445 8,237 10,985
Market Capitalization		 3,984 4,215 5,394 7,692 9,920 17,277 13,458 12,780 11,279 8,054 11,049
Book Value per Share		 $23.63 $25.44 $28.72 $30.86 $36.14 $40.19 $43.38 $12.49 $13.13 $12.24 $13.47
Tangible Book Value per Share		 $3.70 ($2.18) $0.93 ($3.88) $3.57 $2.67 $8.87 $3.55 $3.74 $3.65 $5.30
Total Capital		 975 1,358 1,418 1,674 1,744 1,917 1,957 2,320 2,388 2,265 2,308
Total Debt		 95 409 339 509 363 345 256 354 319 346 200
Total Long-Term Debt		 92 344 339 493 344 329 243 350 319 346 200
Net Debt		 -0.58 251 157 343 92 114 8.88 149 166 184 -65
Capital Expenditures (CapEx)		 17 15 21 25 52 44 45 38 63 29 24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 108 120 137 160 162 143 195 292 305 270 316
Debt-free Net Working Capital (DFNWC)		 204 278 319 327 433 375 442 496 458 432 581
Net Working Capital (NWC)		 200 213 319 311 414 358 430 493 458 432 581
Net Nonoperating Expense (NNE)		 2.20 5.86 10 30 -99 84 -4.19 -33 19 2.83 8.47
Net Nonoperating Obligations (NNO)		 -0.58 251 157 343 92 114 14 149 156 171 -65
Total Depreciation and Amortization (D&A)		 43 60 64 78 83 88 101 107 112 110 97
Debt-free, Cash-free Net Working Capital to Revenue		 21.58% 21.29% 21.32% 22.48% 21.90% 15.39% 17.64% 25.70% 26.33% 22.16% 26.01%
Debt-free Net Working Capital to Revenue		 40.78% 49.31% 49.59% 45.73% 58.58% 40.26% 39.98% 43.68% 39.52% 35.46% 47.79%
Net Working Capital to Revenue		 40.03% 37.74% 49.59% 43.50% 56.08% 38.49% 38.85% 43.37% 39.52% 35.46% 47.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.70 $0.51 $0.84 $0.64 $1.50 $0.91 $1.73 $1.81 $1.07 $0.47 $1.17
Adjusted Weighted Average Basic Shares Outstanding		 148.78M 149.25M 149.90M 151.12M 152.80M 154.99M 156.88M 157.18M 157.71M 157.52M 155.96M
Adjusted Diluted Earnings per Share		 $0.70 $0.51 $0.83 $0.62 $1.46 $0.87 $1.66 $1.76 $1.05 $0.46 $1.16
Adjusted Weighted Average Diluted Shares Outstanding		 149.30M 150M 152.22M 155.57M 157.60M 161.93M 164.12M 161.86M 160.77M 159.72M 157.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 149.19M 149.53M 150.93M 152.25M 154.20M 156.32M 156.85M 158.17M 158.60M 155.55M 156.82M
Normalized Net Operating Profit after Tax (NOPAT)		 107 82 95 126 131 224 259 252 187 76 190
Normalized NOPAT Margin		 21.38% 14.56% 14.83% 17.62% 17.67% 24.01% 23.42% 22.17% 16.14% 6.25% 15.66%
Pre Tax Income Margin		 29.55% 19.89% 19.59% 15.69% 37.43% 15.92% 27.26% 29.79% 16.02% 8.07% 19.81%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 85.23 16.17 13.32 6.13 15.37 11.59 27.58 30.89 12.59 12.11 25.55
NOPAT to Interest Expense		 61.03 11.13 13.39 5.80 6.80 16.02 22.89 22.47 11.89 8.96 19.76
EBIT Less CapEx to Interest Expense		 75.56 14.11 11.27 4.96 12.68 8.41 23.61 27.48 8.59 8.76 23.04
NOPAT Less CapEx to Interest Expense		 51.36 9.07 11.33 4.63 4.11 12.85 18.92 19.06 7.90 5.60 17.25
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 45.57% 62.20% 38.03% 50.34% 21.33% 35.55% 19.07% 17.62% 29.99% 68.65% 27.45%
Augmented Payout Ratio		 45.57% 62.20% 38.03% 66.38% 43.18% 66.48% 80.25% 24.47% 77.61% 444.31% 50.36%

Quarterly Metrics And Ratios for Bio-Techne

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 156,453,292.00 156,568,751.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 156,453,292.00 156,568,751.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.33 0.35
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.37% 3.16% 1.59% 4.52% 8.96% 4.20% 3.55% -1.00% -0.39% -1.51% 1.33%
EBITDA Growth		 -35.31% -12.01% -39.17% -12.54% 14.33% -29.72% -95.60% 5.69% 6.26% 50.37% 2,926.35%
EBIT Growth		 -50.82% -16.47% -51.52% -18.94% 28.42% -42.23% -152.07% 19.18% 14.85% 95.04% 411.31%
NOPAT Growth		 -38.83% -23.38% -44.74% -41.81% 23.43% -57.55% -137.41% 13.38% 5.63% 136.85% 443.69%
Net Income Growth		 -45.08% -30.13% -46.23% -34.11% 27.03% -53.96% -143.55% 13.65% 8.94% 125.99% 408.98%
EPS Growth		 -45.16% -27.91% -45.83% -32.26% 29.41% -54.84% -142.31% 14.29% 9.09% 128.57% 427.27%
Operating Cash Flow Growth		 29.09% 60.26% -9.47% 7.59% 1.48% -49.23% 30.07% -56.82% -2.29% 110.75% -2.84%
Free Cash Flow Firm Growth		 -442.42% 76.20% 79.73% 120.00% 122.81% 174.11% 282.26% 92.09% 60.99% 246.80% -11.88%
Invested Capital Growth		 22.92% 5.90% 5.18% -2.15% -2.22% -1.32% -6.06% -5.39% -4.63% -5.77% -2.24%
Revenue Q/Q Growth		 -1.57% 11.31% 0.88% -5.44% 2.62% 6.45% 0.25% -9.59% 3.25% 5.25% 3.14%
EBITDA Q/Q Growth		 -21.65% 43.31% -21.66% -7.54% 2.42% -5.26% -95.09% 2,113.96% 9.96% 25.89% -1.25%
EBIT Q/Q Growth		 -32.63% 76.29% -31.61% -12.33% 6.73% -9.72% -161.64% 299.75% 14.27% 38.62% -1.61%
NOPAT Q/Q Growth		 -45.61% 72.12% -17.03% -25.08% 15.37% -40.80% -173.11% 327.05% 7.49% 32.74% 6.09%
Net Income Q/Q Growth		 -46.14% 78.62% -17.27% -17.22% 3.84% -35.26% -178.26% 316.00% -0.46% 34.30% 7.00%
EPS Q/Q Growth		 -45.16% 82.35% -16.13% -19.23% 4.76% -36.36% -178.57% 318.18% 0.00% 33.33% 12.50%
Operating Cash Flow Q/Q Growth		 39.97% -2.56% -6.78% -15.37% 32.02% -51.25% 138.82% -71.91% 198.75% 5.16% 10.10%
Free Cash Flow Firm Q/Q Growth		 6.04% 81.83% 8.04% 227.38% 7.16% -40.96% 126.17% 34.25% -10.19% 27.17% -42.53%
Invested Capital Q/Q Growth		 -1.79% -0.79% -0.31% 0.74% -1.86% 0.13% -5.10% 1.46% -1.07% -1.08% -1.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 64.78% 67.43% 66.43% 63.23% 65.27% 67.86% 62.72% 65.65% 64.65% 66.88% 65.82%
EBITDA Margin		 22.45% 31.08% 24.14% 23.60% 23.55% 20.96% 1.03% 25.13% 26.76% 32.00% 30.64%
Operating Margin		 13.94% 22.08% 14.97% 13.81% 15.96% 12.24% -7.53% 16.63% 18.41% 24.24% 23.13%
EBIT Margin		 12.25% 22.08% 14.97% 13.88% 14.43% 12.24% -7.53% 16.63% 18.41% 24.24% 23.13%
Profit (Net Income) Margin		 10.08% 16.17% 13.26% 11.61% 11.75% 7.14% -5.58% 13.33% 12.85% 16.39% 17.01%
Tax Burden Percent		 82.26% 80.31% 97.43% 83.64% 81.37% 59.02% 77.34% 79.57% 74.84% 71.67% 77.28%
Interest Burden Percent		 100.00% 91.17% 90.92% 100.00% 100.00% 98.88% 95.80% 100.70% 93.25% 94.34% 95.16%
Effective Tax Rate		 17.74% 19.69% 2.57% 16.36% 18.63% 40.98% 0.00% 20.43% 25.16% 28.33% 22.72%
Return on Invested Capital (ROIC)		 6.44% 9.43% 7.79% 5.97% 6.98% 3.94% -2.98% 7.38% 7.79% 9.83% 10.51%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.81% 7.25% 5.13% 6.05% 5.17% 3.81% -3.57% 7.59% 5.15% 6.33% 5.30%
Return on Net Nonoperating Assets (RNNOA)		 0.29% 0.81% 0.39% 0.58% 0.52% 0.38% -0.29% 0.48% 0.26% 0.27% 0.14%
Return on Equity (ROE)		 6.73% 10.24% 8.18% 6.55% 7.50% 4.32% -3.27% 7.86% 8.06% 10.10% 10.65%
Cash Return on Invested Capital (CROIC)		 -8.83% 4.55% 3.58% 9.37% 9.91% 7.59% 9.79% 9.24% 8.60% 11.30% 11.47%
Operating Return on Assets (OROA)		 5.51% 9.58% 6.50% 5.92% 6.39% 5.52% -3.49% 7.69% 8.62% 11.30% 10.92%
Return on Assets (ROA)		 4.53% 7.01% 5.75% 4.95% 5.20% 3.22% -2.59% 6.16% 6.01% 7.64% 8.03%
Return on Common Equity (ROCE)		 6.73% 10.24% 8.18% 6.55% 7.50% 4.32% -3.27% 7.86% 8.06% 10.10% 10.65%
Return on Equity Simple (ROE_SIMPLE)		 11.42% 10.08% 0.00% 7.05% 7.61% 6.52% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 31 54 45 33 39 23 -17 38 41 54 57
NOPAT Margin		 11.47% 17.73% 14.58% 11.55% 12.99% 7.23% -5.27% 13.23% 13.78% 17.37% 17.87%
Net Nonoperating Expense Percent (NNEP)		 2.62% 2.18% 2.65% -0.08% 1.81% 0.13% 0.60% -0.21% 2.64% 3.50% 5.21%
Return On Investment Capital (ROIC_SIMPLE)		 1.30% - - - 1.62% 0.97% -0.74% 1.67% 1.79% 2.37% 2.49%
Cost of Revenue to Revenue		 35.22% 32.57% 33.57% 36.77% 34.73% 32.14% 37.28% 34.35% 35.35% 33.12% 34.18%
SG&A Expenses to Revenue		 42.43% 36.86% 43.63% 41.17% 40.89% 47.84% 62.04% 40.56% 38.43% 35.11% 35.24%
R&D to Revenue		 8.41% 8.49% 7.84% 8.25% 8.42% 7.77% 8.21% 8.46% 7.82% 7.53% 7.46%
Operating Expenses to Revenue		 50.84% 45.35% 51.46% 49.41% 49.31% 55.62% 70.25% 49.01% 46.24% 42.64% 42.69%
Earnings before Interest and Taxes (EBIT)		 33 67 46 40 43 39 -24 48 54 75 74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 61 94 74 68 70 66 3.25 72 79 100 98
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.19 5.48 5.45 5.93 5.51 4.59 4.20 4.40 4.56 3.92 5.24
Price to Tangible Book Value (P/TBV)		 28.07 21.36 19.15 18.92 17.53 15.30 14.07 13.59 13.18 10.37 13.32
Price to Revenue (P/Rev)		 10.61 9.57 9.73 10.82 9.57 7.67 6.60 7.11 7.54 6.75 9.09
Price to Earnings (P/E)		 54.20 54.39 67.09 84.11 72.37 70.40 109.72 110.96 112.98 74.63 60.76
Dividend Yield		 0.42% 0.46% 0.45% 0.40% 0.44% 0.55% 0.62% 0.58% 0.54% 0.61% 0.45%
Earnings Yield		 1.84% 1.84% 1.49% 1.19% 1.38% 1.42% 0.91% 0.90% 0.89% 1.34% 1.65%
Enterprise Value to Invested Capital (EV/IC)		 5.54 5.06 5.14 5.71 5.26 4.29 3.94 4.15 4.41 3.93 5.38
Enterprise Value to Revenue (EV/Rev)		 10.88 9.78 9.87 10.92 9.67 7.82 6.75 7.24 7.61 6.74 9.04
Enterprise Value to EBITDA (EV/EBITDA)		 32.89 30.84 36.94 42.63 37.46 33.45 38.68 40.77 41.91 32.14 31.98
Enterprise Value to EBIT (EV/EBIT)		 46.40 44.19 57.77 67.77 58.36 55.01 79.91 80.13 79.09 53.11 44.64
Enterprise Value to NOPAT (EV/NOPAT)		 52.05 50.58 61.17 78.41 67.87 68.09 108.07 109.21 111.35 71.33 57.71
Enterprise Value to Operating Cash Flow (EV/OCF)		 45.08 36.78 38.28 42.14 37.96 35.71 28.65 35.06 37.10 27.70 37.61
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 114.24 147.48 60.24 52.49 56.19 39.01 43.72 50.04 33.79 46.33
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.23 0.19 0.15 0.14 0.14 0.16 0.18 0.15 0.13 0.10 0.09
Long-Term Debt to Equity		 0.23 0.19 0.15 0.14 0.14 0.16 0.18 0.15 0.13 0.10 0.09
Financial Leverage		 0.08 0.11 0.08 0.10 0.10 0.10 0.08 0.06 0.05 0.04 0.03
Leverage Ratio		 1.34 1.36 1.32 1.33 1.34 1.33 1.32 1.28 1.27 1.27 1.28
Compound Leverage Factor		 1.34 1.24 1.20 1.33 1.34 1.32 1.26 1.29 1.18 1.19 1.22
Debt to Total Capital		 18.54% 16.19% 13.36% 12.30% 12.61% 14.05% 15.28% 13.24% 11.45% 8.75% 8.66%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 18.54% 16.19% 13.36% 12.30% 12.61% 14.05% 15.28% 13.24% 11.45% 8.75% 8.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 81.46% 83.81% 86.64% 87.70% 87.39% 85.95% 84.72% 86.76% 88.55% 91.25% 91.34%
Debt to EBITDA		 1.18 1.06 1.03 1.00 0.97 1.17 1.62 1.39 1.18 0.79 0.58
Net Debt to EBITDA		 0.82 0.67 0.54 0.37 0.40 0.67 0.86 0.72 0.39 -0.04 -0.19
Long-Term Debt to EBITDA		 1.18 1.06 1.03 1.00 0.97 1.17 1.62 1.39 1.18 0.79 0.58
Debt to NOPAT		 1.87 1.74 1.70 1.84 1.76 2.38 4.54 3.72 3.13 1.75 1.05
Net Debt to NOPAT		 1.30 1.09 0.89 0.69 0.72 1.36 2.41 1.92 1.05 -0.09 -0.34
Long-Term Debt to NOPAT		 1.87 1.74 1.70 1.84 1.76 2.38 4.54 3.72 3.13 1.75 1.05
Altman Z-Score		 10.81 10.75 12.03 14.12 12.99 10.23 8.79 10.63 12.15 12.00 15.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.37 4.08 3.87 4.56 3.94 3.71 3.46 4.22 4.54 4.49 4.55
Quick Ratio		 2.54 2.49 2.47 2.89 2.45 2.23 2.10 2.28 2.55 2.77 2.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -388 -71 -65 83 89 52 118 159 143 181 104
Operating Cash Flow to CapEx		 559.18% 492.59% 419.89% 696.57% 1,236.56% 406.20% 2,320.44% 3,697.72% 1,391.84% 953.79% 1,125.19%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.43 0.43 0.43 0.44 0.45 0.46 0.46 0.47 0.47 0.47
Accounts Receivable Turnover		 5.84 5.20 5.04 5.47 5.62 5.20 5.44 5.97 6.04 5.36 5.74
Inventory Turnover		 2.21 2.20 2.22 2.18 2.23 2.23 2.33 2.17 2.15 2.16 2.16
Fixed Asset Turnover		 5.00 4.94 4.86 4.83 4.94 4.88 4.91 4.92 5.02 4.99 5.09
Accounts Payable Turnover		 13.53 13.68 12.23 13.55 12.72 13.68 13.57 13.66 14.24 15.39 16.00
Days Sales Outstanding (DSO)		 62.51 70.25 72.41 66.71 64.91 70.21 67.08 61.13 60.44 68.08 63.60
Days Inventory Outstanding (DIO)		 165.39 166.19 164.70 167.63 163.88 163.37 156.92 168.15 169.98 168.71 169.00
Days Payable Outstanding (DPO)		 26.97 26.68 29.83 26.94 28.69 26.69 26.90 26.73 25.63 23.71 22.82
Cash Conversion Cycle (CCC)		 200.94 209.76 207.28 207.40 200.10 206.89 197.10 202.55 204.79 213.08 209.78
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,250 2,232 2,225 2,242 2,200 2,203 2,090 2,121 2,098 2,075 2,044
Invested Capital Turnover		 0.56 0.53 0.53 0.52 0.54 0.55 0.57 0.56 0.57 0.57 0.59
Increase / (Decrease) in Invested Capital		 420 124 110 -49 -50 -29 -135 -121 -102 -127 -47
Enterprise Value (EV)		 12,462 11,285 11,445 12,789 11,567 9,458 8,237 8,808 9,250 8,166 10,985
Market Capitalization		 12,150 11,042 11,279 12,677 11,445 9,269 8,054 8,653 9,163 8,176 11,049
Book Value per Share		 $12.42 $12.81 $13.13 $13.48 $13.08 $12.77 $12.24 $12.64 $12.91 $13.33 $13.47
Tangible Book Value per Share		 $2.74 $3.29 $3.74 $4.22 $4.11 $3.83 $3.65 $4.09 $4.46 $5.04 $5.30
Total Capital		 2,411 2,403 2,388 2,439 2,378 2,348 2,265 2,266 2,271 2,285 2,308
Total Debt		 447 389 319 300 300 330 346 300 260 200 200
Total Long-Term Debt		 447 389 319 300 300 330 346 300 260 200 200
Net Debt		 311 244 166 112 122 189 184 155 87 -9.82 -65
Capital Expenditures (CapEx)		 15 16 18 9.17 6.82 10 4.23 0.75 5.92 9.09 8.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 320 316 305 319 296 317 270 320 324 325 316
Debt-free Net Working Capital (DFNWC)		 455 461 458 506 473 458 432 465 497 535 581
Net Working Capital (NWC)		 455 461 458 506 473 458 432 465 497 535 581
Net Nonoperating Expense (NNE)		 3.80 4.75 4.05 -0.15 3.70 0.26 0.98 -0.26 2.75 3.06 2.78
Net Nonoperating Obligations (NNO)		 286 218 156 103 121 185 171 155 87 -9.82 -65
Total Depreciation and Amortization (D&A)		 28 27 28 28 27 28 27 24 25 24 24
Debt-free, Cash-free Net Working Capital to Revenue		 27.93% 27.33% 26.33% 27.22% 24.74% 26.26% 22.16% 26.30% 26.66% 26.84% 26.01%
Debt-free Net Working Capital to Revenue		 39.77% 39.92% 39.52% 43.23% 39.58% 37.89% 35.46% 38.21% 40.89% 44.17% 47.79%
Net Working Capital to Revenue		 39.77% 39.92% 39.52% 43.23% 39.58% 37.89% 35.46% 38.21% 40.89% 44.17% 47.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.17 $0.31 $0.26 $0.21 $0.22 $0.14 ($0.10) $0.25 $0.24 $0.33 $0.35
Adjusted Weighted Average Basic Shares Outstanding		 157.53M 157.31M 157.71M 158.53M 158.43M 157.37M 157.52M 155.46M 155.84M 156.33M 155.96M
Adjusted Diluted Earnings per Share		 $0.17 $0.31 $0.26 $0.21 $0.22 $0.14 ($0.11) $0.24 $0.24 $0.32 $0.36
Adjusted Weighted Average Diluted Shares Outstanding		 160.06M 160.50M 160.77M 161.12M 160.63M 158.94M 159.72M 156.36M 157.00M 157.40M 157.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.26 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 157.19M 157.58M 158.60M 158.89M 158.09M 156.77M 155.55M 155.81M 156.45M 156.57M 156.82M
Normalized Net Operating Profit after Tax (NOPAT)		 31 54 45 33 39 23 -17 38 41 54 57
Normalized NOPAT Margin		 11.47% 17.73% 14.58% 11.55% 12.99% 7.23% -5.27% 13.23% 13.78% 17.37% 17.87%
Pre Tax Income Margin		 12.25% 20.13% 13.61% 13.88% 14.43% 12.11% -7.21% 16.75% 17.16% 22.87% 22.01%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 22.48% 24.82% 29.99% 33.48% 32.02% 38.45% 68.65% 64.30% 61.50% 45.47% 27.45%
Augmented Payout Ratio		 58.19% 64.25% 77.61% 33.48% 79.84% 171.88% 444.31% 417.90% 308.26% 136.82% 50.36%

Financials Breakdown Chart

Key Financial Trends

Bio-Techne’s latest financial data shows a meaningful recovery in profitability and cash generation. Revenue increased from $286.6 million in fiscal Q1 2026 to $321.2 million in Q4 2026, marking growth in each reported quarter. Q4 revenue was also up approximately 1.3% from $317.0 million in Q4 2025.

Profitability improved sharply from the prior-year period. Q4 2026 operating income was $74.3 million, compared with a $23.9 million operating loss in Q4 2025, while net income rose to $54.6 million from a $17.7 million loss. The latest quarter produced a 65.8% gross margin, 23.1% operating margin and 17.0% net margin.

Cash generation has also strengthened. Operating cash flow rose from $27.6 million in Q1 2026 to $95.4 million in Q4, exceeding net income by approximately $40.9 million in the latest quarter. However, Bio-Techne continued to use cash for share repurchases, dividends and debt-related activities.

  • Revenue momentum improved: Quarterly revenue increased sequentially from $286.6 million in Q1 2026 to $321.2 million in Q4 2026.
  • Profitability recovered significantly: Q4 2026 operating income reached $74.3 million versus a $23.9 million operating loss in Q4 2025.
  • Net income returned to strong growth: Q4 net income of $54.6 million compared with a $17.7 million loss in the prior-year quarter.
  • Cash flow improved throughout fiscal 2026: Operating cash flow climbed from $27.6 million in Q1 to $95.4 million in Q4.
  • Liquidity remained strong: At March 31, 2026, current assets of $688.1 million were about 4.5 times current liabilities of $153.3 million.
  • Debt declined: Long-term debt fell to $200.0 million at March 31, 2026, from $300.0 million at September 30, 2025 and $447.0 million at December 31, 2023.
  • Shareholder returns continued: Bio-Techne repurchased $41.7 million of common stock in Q4 2026 and maintained its quarterly dividend at $0.08 per share.
  • Operating leverage remains important: Selling, general and administrative expense declined from the unusually high $196.6 million reported in Q4 2025, but was still $113.2 million in Q4 2026.
  • Cash increased despite capital allocation: Q4 cash flow produced a $54.9 million increase in cash after $8.5 million of capital expenditures and $33.2 million of net financing outflows.
  • Asset concentration creates impairment risk: Goodwill and intangible assets totaled approximately $1.30 billion, or roughly 51% of reported assets at March 31, 2026.

Investor takeaway: The data points to improving demand, stronger margins and substantially better free-cash-flow potential than Bio-Techne demonstrated during the prior-year downturn. The balance sheet is also healthier because debt has declined and liquidity remains ample. Investors should nevertheless monitor whether the Q4 margin recovery is sustainable, as well as the company’s large goodwill and intangible-asset balances and its continued use of cash for buybacks and dividends.

09/07/26 09:45 AM ETAI Generated. May Contain Errors.

Bio-Techne Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bio-Techne's financial year ends in June. Their financial year 2026 ended on June 30, 2026.

Bio-Techne's net income appears to be on an upward trend, with a most recent value of $181.86 million in 2026, rising from $104.48 million in 2016. The previous period was $73.40 million in 2025. Find out what analysts predict for Bio-Techne in the coming months.

Bio-Techne's total operating income in 2026 was $251.89 million, based on the following breakdown:
  • Total Gross Profit: $799.07 million
  • Total Operating Expenses: $547.18 million

Over the last 10 years, Bio-Techne's total revenue changed from $499.02 million in 2016 to $1.22 billion in 2026, a change of 143.5%.

Bio-Techne's total liabilities were at $478.51 million at the end of 2026, a 25.1% decrease from 2025, and a 91.2% increase since 2016.

In the past 10 years, Bio-Techne's cash and equivalents has ranged from $64.24 million in 2016 to $264.71 million in 2026, and is currently $264.71 million as of their latest financial filing in 2026.

Over the last 10 years, Bio-Techne's book value per share changed from 23.63 in 2016 to 13.47 in 2026, a change of -43.0%.


Related Companies

Financial statements for NASDAQ:TECH last updated on 8/24/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel